Drawing for OPTIKINE

USPTO serial 50018552

OPTIKINE

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
CIURPITA, DREW PETER FISHER
Law office
TMO LAW OFFICE 137

What this means

Status 638 means your application has been assigned to a USPTO examining attorney who is reviewing it against federal law and existing marks. The first office action or approval usually follows within a few months. Monitor TSDR for the examiner's first action. No filing is required until an office action or other requirement is issued.

Status 638: Status 638 means your application has been assigned to a USPTO examining attorney who is reviewing it against federal law and existing marks. The first office action or approval usually follows within a few months.

Need help with OPTIKINE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Dianne M. Smith-Misemer

Dianne M. Smith-Misemer HOVEY WILLIAMS LLP10801 Mastin St., Suite 1000Overland Park, KS 66210United States

Goods and services

ClassDescriptionStatusFirst use
001Recombinant cytokine proteins in raw material form for scientific and medical research use; Recombinant cytokine proteins for use in manufacture of pharmaceutical products, veterinary preparations, cellular therapies, gene therapies, regenerative medicines, and vaccines; Chemicals, namely, non-animal derived cell culture media for promoting cell growth, optimization, and productivity, for scientific and research use; Non-animal derived cell culture media for promoting cell growth, optimization, and productivity, for scientific, laboratory and medical researchACTIVE—
005Chemicals, namely, non-animal derived cell culture media for promoting cell growth, optimization, and productivity, for medical or veterinary purposes; Recombinant cytokine proteins for use as cell growth media for growing cells for clinical use; Recombinant cytokine proteins for use as reagents for clinical medical purposes; Recombinant cytokine protein arrays for clinical medical diagnosis purposes; Recombinant cytokine proteins sold as a component ingredient of therapeutic pharmaceuticals for the treatment of immune system related diseases and disorders; Recombinant cytokine proteins for use as reagents for medical use, for the optimization of in vitro expansion of cells; Pharmaceutical preparations, namely, cytokine drugs for the optimization of in vitro expansion of cellsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 12, 2026DOCKASSIGNED TO EXAMINER—
Sep 16, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 28, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 28, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance